A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES

Trial Profile

A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs Cobimetinib (Primary) ; Onartuzumab (Primary) ; Vemurafenib (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 01 Aug 2016 Status changed from completed to withdrawn prior to enrolment.
    • 05 Oct 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Jul 2014 Planned End Date changed from 1 Sep 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top